First Trust Specialty Finance and Financial Opportunities Fund (FGB) Forms $6.52 Double Bottom; Profile of 8 Analysts Covering Omnicell, Inc. (OMCL)

First Trust Specialty Finance and Financial Opportunities Fund (FGB) formed double bottom with $6.32 target or 3.00% below today’s $6.52 share price. First Trust Specialty Finance and Financial Opportunities Fund (FGB) has $ valuation. The stock increased 0.93% or $0.06 during the last trading session, reaching $6.52. About 45,358 shares traded. First Trust Specialty Finance and Financial Opportunities Fund (NYSE:FGB) has risen 20.16% since January 23, 2017 and is uptrending. It has outperformed by 3.46% the S&P500.

Among 9 analysts covering Omnicell (NASDAQ:OMCL), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Omnicell had 23 analyst reports since July 31, 2015 according to SRatingsIntel. As per Tuesday, December 6, the company rating was maintained by Benchmark. On Thursday, October 19 the stock rating was maintained by Oppenheimer with “Buy”. Oppenheimer maintained Omnicell, Inc. (NASDAQ:OMCL) on Friday, July 31 with “Outperform” rating. Topeka Capital Markets maintained Omnicell, Inc. (NASDAQ:OMCL) rating on Friday, July 31. Topeka Capital Markets has “Buy” rating and $40 target. Cantor Fitzgerald maintained the shares of OMCL in report on Tuesday, December 5 with “Buy” rating. The company was maintained on Friday, October 27 by Piper Jaffray. Sidoti upgraded Omnicell, Inc. (NASDAQ:OMCL) on Monday, September 28 to “Buy” rating. The stock of Omnicell, Inc. (NASDAQ:OMCL) earned “Outperform” rating by FBR Capital on Friday, October 30. As per Monday, October 30, the company rating was maintained by Craig Hallum. Benchmark initiated it with “Buy” rating and $33.0 target in Thursday, January 7 report. See Omnicell, Inc. (NASDAQ:OMCL) latest ratings:

05/12/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $60.0 Maintain
05/12/2017 Broker: Oppenheimer Rating: Buy New Target: $55.0 Maintain
30/10/2017 Broker: Craig Hallum Rating: Buy New Target: $62.0 Maintain
27/10/2017 Broker: Piper Jaffray Rating: Hold New Target: $38.0 Maintain
27/10/2017 Broker: Oppenheimer Rating: Buy New Target: $55.0 Maintain
26/10/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $58.0 Maintain
19/10/2017 Broker: Oppenheimer Rating: Buy New Target: $55.0 Maintain
28/07/2017 Broker: Piper Jaffray Rating: Hold New Target: $40.0000 Maintain
28/07/2017 Broker: Craig Hallum Rating: Buy New Target: $52.0000
28/07/2017 Broker: Oppenheimer Rating: Buy New Target: $53.0000 Maintain

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company has market cap of $1.95 billion. The firm operates through two divisions, Automation and Analytics, and Medication Adherence. It currently has negative earnings. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Savvy Mobile Medication Workstation, which provides a platform for hospital information systems.

Since August 7, 2017, it had 0 insider purchases, and 9 insider sales for $5.00 million activity. DREW J CHRISTOPHER had sold 11,375 shares worth $581,958 on Tuesday, August 8. 18,054 shares valued at $908,273 were sold by Kuipers Peter J. on Wednesday, August 9. 15,109 shares were sold by Seim Robin Gene, worth $768,483. On Tuesday, September 5 PETERSMEYER GARY S sold $51,734 worth of Omnicell, Inc. (NASDAQ:OMCL) or 1,000 shares. LIPPS RANDALL A sold $552,537 worth of stock or 10,625 shares. The insider JOHNSTON DAN S sold 16,400 shares worth $801,291. On Monday, August 7 Taborga Jorge R. sold $1.06 million worth of Omnicell, Inc. (NASDAQ:OMCL) or 20,719 shares.

Investors sentiment decreased to 1.02 in 2017 Q3. Its down 0.41, from 1.43 in 2017Q2. It dived, as 8 investors sold Omnicell, Inc. shares while 79 reduced holdings. 29 funds opened positions while 60 raised stakes. 37.10 million shares or 0.94% less from 37.45 million shares in 2017Q2 were reported. Moreover, Juncture Wealth Strategies Limited Company has 0.79% invested in Omnicell, Inc. (NASDAQ:OMCL) for 27,500 shares. Schwab Charles Mgmt owns 162,614 shares for 0.01% of their portfolio. Aqr Capital Management reported 7,674 shares stake. Sfe Inv Counsel reported 15,194 shares or 0.33% of all its holdings. Northern Tru reported 508,022 shares stake. Trillium Asset Mngmt Limited Liability Corporation reported 32,077 shares stake. Comml Bank Of Montreal Can holds 1,702 shares. Deutsche Savings Bank Ag invested 0% in Omnicell, Inc. (NASDAQ:OMCL). Synovus Financial invested in 0.02% or 21,009 shares. Envestnet Asset Mgmt stated it has 0% in Omnicell, Inc. (NASDAQ:OMCL). Scout Investments has 0.21% invested in Omnicell, Inc. (NASDAQ:OMCL) for 151,750 shares. Eagle Asset Management reported 0.3% of its portfolio in Omnicell, Inc. (NASDAQ:OMCL). Alliancebernstein L P owns 50,646 shares. Aperio Group Inc Ltd Liability Com invested 0.01% in Omnicell, Inc. (NASDAQ:OMCL). Spectrum Group Incorporated reported 6 shares or 0% of all its holdings.

The stock decreased 0.39% or $0.2 during the last trading session, reaching $51.5. About 146,755 shares traded. Omnicell, Inc. (NASDAQ:OMCL) has risen 33.21% since January 23, 2017 and is uptrending. It has outperformed by 16.51% the S&P500.